위암 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global gastric cancer drugs market size is expected to reach USD 12.86 Billion in 2034 from USD 5.39 Billion in 2025, growing at a CAGR of 10.14% during 2026-2034.This market is developing as pharmaceutical companies and healthcare systems seek improved treatment options for gastric and gastroesophageal cancers. Treatment approaches can include chemotherapy, targeted therapies, immunotherapy, and other specialized interventions depending on tumor characteristics and patient needs. According to the World Health Organization, stomach cancer remains an important global cancer burden, creating continued demand for effective diagnosis and treatment. Increasing understanding of molecular characteristics is also supporting the development of therapies designed for specific patient groups. Advances in oncology research are therefore creating opportunities for pharmaceutical companies developing more precise and effective treatment strategies.

The gastric cancer drugs market is being influenced by progress in biomarker testing, targeted therapies, and immune-based treatments. Researchers are increasingly identifying molecular characteristics that can help determine whether patients may benefit from particular therapies. Companion diagnostics and genomic testing are consequently becoming more relevant to treatment selection. Pharmaceutical companies are also investigating combinations of immunotherapies, targeted agents, and conventional treatments to improve outcomes across different disease stages. Clinical research remains important because gastric cancer is biologically diverse, requiring treatment approaches that can address differences in tumor biology and individual patient characteristics.

Future prospects are supported by continued oncology research and the development of personalized treatment strategies. New biomarkers could expand the number of patients eligible for targeted or immune-based therapies, while combination approaches may improve treatment effectiveness. Greater access to molecular testing could also support more precise treatment selection in developing healthcare systems. Drug developers that demonstrate meaningful clinical benefits while addressing unmet treatment needs are likely to find significant opportunities. The market should continue evolving toward biomarker-driven therapies, combination regimens, and increasingly individualized approaches as researchers deepen their understanding of gastric cancer biology.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• Imatinib (Oral Formulations, Injectable Formulations, Combination Therapies)
• Trastuzumab (Monotherapy, Combination Therapy with Chemotherapy, Biosimilars of Trastuzumab)
• Other Types (Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications)

By Route of Administration

• Oral
• Parenteral

By End User

• Hospitals
• Clinics
• Cancer Specialty Centers

COMPANIES PROFILED

• Arlak Biotech, Astellas Pharma Inc., AstraZeneca plc, BeiGene, Biocad, Biocon, Bristol-Myers Squibb, CARsgen Therapeutics, Celon Pharma, Celltrion Inc., CStone Pharma, Daiichi Sankyo, Eli Lilly and Company, Eurofarma Laboratorios S.A., F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline plc, Jiangsu HengRui Medicine, Johnson & Johnson, JW Therapeutics, Merck & Co. Inc., Mylan Laboratories, Novartis Oncology, PV Pharma Healthcare, Pfizer Inc., Sandoz AG (Novartis), Sanofi, Takeda Pharmaceuticals, Teva Pharmaceutical Industries Ltd., TUTEUR / Pierre Fabre Group

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GASTRIC CANCER DRUGS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Imatinib (Oral Formulations, Injectable Formulations, Combination Therapies) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Trastuzumab (Monotherapy, Combination Therapy with Chemotherapy, Biosimilars of Trastuzumab) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Other Types (Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GASTRIC CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GASTRIC CANCER DRUGS MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Cancer Specialty Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GASTRIC CANCER DRUGS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Route Of Administration
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Route Of Administration
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Route Of Administration
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Route Of Administration
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Route Of Administration
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL GASTRIC CANCER DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Arlak Biotech
  • 9.2.2 Astellas Pharma Inc
  • 9.2.3 AstraZeneca Plc
  • 9.2.4 BeiGene
  • 9.2.5 Biocad
  • 9.2.6 Biocon
  • 9.2.7 Bristol-Myers Squibb
  • 9.2.8 CARsgen Therapeutics
  • 9.2.9 Celon Pharma
  • 9.2.10 Celltrion Inc
  • 9.2.11 CStone Pharma
  • 9.2.12 Daiichi Sankyo
  • 9.2.13 Eli Lilly And Company
  • 9.2.14 Eurofarma Laboratorios S.A
  • 9.2.15 F. Hoffmann-La Roche
  • 9.2.16 Gilead Sciences
  • 9.2.17 GlaxoSmithKline Plc
  • 9.2.18 Jiangsu HengRui Medicine
  • 9.2.19 Johnson & Johnson
  • 9.2.20 JW Therapeutics
  • 9.2.21 Merck & Co. Inc
  • 9.2.22 Mylan Laboratories
  • 9.2.23 Novartis Oncology
  • 9.2.24 PV Pharma Healthcare
  • 9.2.25 Pfizer Inc
  • 9.2.26 Sandoz AG (Novartis)
  • 9.2.27 Sanofi
  • 9.2.28 Takeda Pharmaceuticals
  • 9.2.29 Teva Pharmaceutical Industries Ltd
  • 9.2.30 TUTEUR / Pierre Fabre Group